Efficacy And Safety Of A Treatment For Eczema (Atopic Dermatitis)
Posted Date: Sep 16, 2019
- Investigator: Alan Fleischer
- Specialties: Dermatology, Skin Disease
- Type of Study: Drug
This is a placebo-controlled study in adult and adolescent participants with moderate to severe atopic dermatitis. The study drug is an antibody that blocks a receptor involved with atopic dermatitis development and itchiness. Eligible participants will be randomly distributed to the experimental (drug) or placebo group in a ratio (2:1). Eligible participants will receive subcutaneous injections for 16-weeks. At week 16 visit participants will be evaluated as responders or non-responders. The responders will continue to the maintenance period of the study. The non-responders may be eligible to enroll into a long-term extension study.
Eligible Subjects Must Have Documented History Of Atopic Dermatitis For At Least 2 Years; Easi Score >16; Iga>3; Bsa Involvement >10%; Failure To Achieve Or Maintain Disease Remission; Agree To Apply Moisturizer During The Duration Of The Study; Willing To Comply With All Procedures, Including Recording Daily Diary.
Dermatitis, Antibody, Itchiness
For More Information: